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Objectives: Combination chemotherapy is very active in small cell lung cancer (SCLC), although no improvement in
overall survival (OS) has been done in the last 25 years, with Cisplatin-Etoposide (PE) still considered the world-wide
standard, with an average median survival of about 7–8 months in patients with extended disease (ED).
In 1995, a randomized trial of the Hoosier Group in 171 ED patients showed a significant advantage in overall survival
in patients treated with PEI (Cisplatin, Etoposide and Ifosfamide), compared to PE. Despite that, PEI regimen has not
become a commonly used regimen in SCLC.
Materials and methods: Here we present a retrospective analysis of 46 consecutive patients (30 males and 16
females) with SCLC that were treated at our Institution with PEI regimen: Cisplatin 20 mg/m2, Etoposide
75 mg/m2 and Ifosfamide 1200 mg/m2, day 1 to 4, every 3 weeks.
Patients received a total of 219 cycles of chemotherapy, with a mean of 4,7 cycles per patient. Median age
was 63 (range 59–70); performance status (PS) was 0 in 29 patients (63%), 1 in 13 patients (28%) and 2 in 4
patients (9%).
Results: In 19 limited disease (LD) patients partial response (PR) rate was 74%, and complete response (CR)
was 16%. In 27 ED patients we observed 63% of PR and 26% of CR.
Median time to progression (TTP) was 15.2 months in LD and 7.1 months in ED with median overall survival
(OS) of 28.2 and 11.8 months, respectively.
Toxicity was manageable, with a high dose intensity.
Conclusions: PEI regimen, in our opinion, may be a possible therapeutic option, with high activity and an
acceptable toxicity profile.
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Neuroendocrine tumors account for approximately 20% of
lung cancers; most of them (≈80%) are SCLC [1]. In 2012,
about 34,000 new cases of SCLC have occurred in the
United States, in the majority attributable to cigarette
smoking [2].
SCLC tends to disseminate early in the course of its
natural history and to grow quickly. Approximately 10%
to 18% of patients present with brain metastases (BM) at
the time of initial diagnosis, and in an additional 40% to
50% will develop BM some time during course of their
disease [3].
Although the incidence of SCLC is decreased in recent
years, it remains a therapeutic challenge, as survival in
patients with limited disease has not changed markedly
over the past 25 years, reaching approximately 20% to
25% at 5 years in the best published series of patients
treated with a multimodality approach [4]
SCLC has a propensity for early hematogenous spread
and for association with paraneoplastic syndromes and
is characterized by its rapid doubling time, high growth
fraction and high, but short-lasting, chemosensitivity.
Paraneoplastic syndromes are more frequently seen in
patients with limited-stage SCLC. Than in those with
extensive-stage disease, but their presence is not un-
equivocally prognostically favourable [5,6].
Chemotherapy is the cornerstone of treatment and
Cisplatin-Etoposide (PE) is still considered the world-
wide standard since over 25 years.
Approximately one-third of patients diagnosed with
SCLC present with LD, with a median survival time of
15–20 months, compared to 7–8 months for patients
with ED. An overall response to combination chemo-
therapy is achieved in 80-90% of LD patients and in 60-
80% of patients with ED [7].
Also the complete response rate is influenced by the
extension of the disease, and is significantly higher in pa-
tients with limited disease (30-50%) compared to pa-
tients with extended disease (15-30%) [8].
Since 90s, several studies have been conducted adding
ifosfamide, an analogue of cyclophosphamide, to the PE
combination, based on his single-agent activity and low
toxicity [9].
The randomized trial of the Hoosier Oncology Group
in 171 ED pts showed a significant advantage in overall
survival in the arm treated with PEI, compared to PE
[10–12]. Despite that, PEI has not become a commonly
used regimen in SCLC, maybe because its less conveni-
ent schedule, requiring 4 consecutive days of chemother-
apy. Relying on its efficacy and manageable toxicity, PEI
was the reference schedule for the treatment of SCLC,
in our centre since 15 years.
Primary objective of the present retrospective study is
to evaluate the activity of PEI in the SCLC in terms of:response rate, time to progression and overall survival,
in patient with LD or ED, treated in first line. Secondary
objective were: the analysis of the dose intensity of
chemotherapy and the evaluation of the tolerability in
terms of toxicity and adverse events.
Material and methods
Between December 1998 and December 2008, 46 con-
secutive patients, older than 18 years, performans status
(PS) <2, with localized (LD) and extensive stage (ED)
SCLC presenting to the Medical Oncology Unit of Reggio
Emilia (Italy) were treated, in first line, with PEI regimen.
All eligible patients had histologically or cytologically
proven SCLC, with measurable disease defined by RECIST
criteria, and received at least one cycle of chemotherapy.
Patients with central nervous system (CNS) metastases
were included in the study.
Pretreatment evaluation included physical examination,
bronchoscopy, total body computed tomography (CT), and
blood tests including a complete blood count, platelet
count, serum creatinine and liver enzyme determination.
The study was approved by our local Ethics commit-
tee. All patients gave written informed consensus before
starting chemotherapy with PEI regimen, and at the time
of data analysis all living patients gave another written
informed consent for the use of their personal data in
the study analysis.
Treatment regimen
The PEI regimen consisted of Cisplatin (P) 20 mg/m2
intravenously (IV) infused in 30 minute, on days 1 to 4
with pre hydration with 1000 ml of 5% dextrose and
2000 ml of 9% normal saline over 2 hours and mannitol-
induced diuresis, Etoposide (E) 75 mg/m2 IV infused in
60 minute, on days 1 to 4 and Ifosfamide (I) 1200 mg/m2
IV infused in 60 minute, on days 1 to 4. Mesna was ad-
ministered at the dose of 1200 mg total by IV bolus before
the first dose of Ifosfamide and then after 4 and 8 hours at
the same dose. Urinalysis was performed daily during the
Ifosfamide treatment. Courses were repeated every 3 week
for 4–6 cycles unless demonstration of disease progression
or inacceptable toxicity.
All patients received intravenous 5-HT3 antagonists and
dexamethasone as antiemetic prophylaxis, for the 4 days of
treatment.
All drugs were reduced by 25% in case of G3 haem-
atological toxicity. In case of febrile neutropenia or
thrombocytopenia, requiring platelet transfusion, all
drugs were reduced by 50% and, in such cases, no re-
escalation was performed.
The use of colony stimulating factors were allowed but
not included as part of the standard treatment regimen.
Drug administration was postponed by 1 week if there
was no full haematological recovery (granulocyte count >
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prior course of chemotherapy. After 1 week of delay, if
the granulocyte count was between 1000/mm3 and
1500/mm3 and/or platelets were between 75.000/mm3
and 100.000/mm3, the doses of all drugs were reduced
by 50%.
Sequential chest irradiation (60 Gy in 30 fractions)
was also administered to patients with LD achieving CR
or partial response (PR).
In patient with LD who achieved complete response
(CR) or partial response (PR) prophylactic cranial irradi-
ation (PCI) was administered; the radiation dose to the
whole brain was 2.5 Gy in 10 fractions.
In selected cases of ED patients the whole brain radio-
therapy (2.5 Gy in 10 fractions) was allowed according
to clinical evaluation.Response and toxicity evaluation
Clinical response was evaluated according to RECIST
criteria (version 1.0).
Clinical response was evaluated by repeating CT scan
and all previously abnormal tests. after three and six cycles.
Toxicity, based on CTCAE toxicity criteria (version 3.0),
was evaluated weekly and at the end of treatment.
Two patients that received only 1 course of chemo-














2 4 9Statistical analysis
Overall survival (OS) time was measured from the date
of diagnosis until death.
Survival time of patients who did not experienced the
event considered during follow up observation was cen-
sored at the time of the last follow-up.
OS analysis was performed in all the 46 patients.
Time to progression (TTP) was calculated from the
start of treatment to the date of first disease progression
or relapse.
TTP of patients who did not experienced the event
considered during follow up period was censored at the
time of the last follow-up or at death, if occurred.
TTP analysis was performed in all the 44 patients con-
sidered evaluable for response.
Main statistical analysis has included: descriptive statistics
of the main patients characteristics (gender, age, stage, per-
formance status, metastatic site), estimation (with Kaplan-
Meier method) and plot of survival probabilities for OS and
TTP (stratified according to stage).
We used the statistical packages R 3.1.0, SAS 9.2 and
PASW Statistics 18.0 (SPSS, Chicago, IL) for data ana-
lysis and visualization.
Dose intensity (DI is the drug dose delivered per time
unit and is expressed as mg/m2 per week) was calcu-
lated for each drug of PEI regimen.Results
Between December 1998 and December 2008, 46 consecu-
tive SCLC patients were treated in first line of chemother-
apy with PEI regimen. The study population was composed
of 30 male (65%) and 16 female (35%) with a median age of
63 years (range 59–70) (Table 1).
Twenty-seven patients (59%) had ED and 19 (41%)
had LD; the PS, graded according to the World Health
Organization (WHO), was 0 in 29 cases (63%); 1 in 13
(28%) and 2 in 4 patients (9%). Metastatic sites were:
lung (85% of the patients), mediastinal node (80%), liver
(28%) and bone 24%. 8 patients had brain metastases at
diagnosis.
There was no substantial significant difference in meta-
static sites between genders: on average, in females group
there were a mean of 2.9 metastatic sites, compared to 2.7
in the males (p-value 0.643, two tailed Poisson test).
Patients received a total of 219 cycles of chemother-
apy, with a mean of 4,7 cycles per patient.
Dose Intensity (DI) was calculated for each drug of PEI
regimen. Based on DI, the patients were divided in two
groups, if they received < 80% or ≥80%. The median DI of
cisplatin was 88%; Ifosfamide was administred with a me-
dian DI of 89% and the median DI of etoposide was 91%.Response and survival
In 19 LD patients an objective response (OR), defined
as complete response (CR) or partial response (PR),
was observed in 17 patients (90%), with 74% of PR and
16% of CR.
In 27 ED patients an OR was observed in 24 cases
(89%), with 63% of PR and 26% of CR (Table 2).
43 patients have died, 27/27 in ED (100%), 16/19 in
LD (84%).
Table 2 Response (46 Pts): limited and extended disease
Limited Disease NV PD No (%) CR No (%) PR No (%) SD No (%)
0 (0) 0 (0) 3 (16) 14 (74) 2 (10)
Extended Disease NV PD No (%) CR No (%) PR No (%) SD No (%)
2(7) 1 (4) 7 (26) 17 (63) 0 (0)
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and TTP up to the fifth year of follow up, stratified ac-
cording to stage.
In the 46 patients, the median Time to Progression
was 8.2 months (95%. CI 7.1-12): 15.2 months in LD and
7.1 months in ED.
The median OS in the 46 patients was 16 months
(95% CI 13–25.9): 28.2 months in LD and 11.8 months
in ED patients.
Toxicity
Despite the use of antiemetic treatment, nausea was very
common on the days of cisplatin infusion; however
vomiting occurred only in 14% of patients.
Myelosuppression was the most frequent adverse event,
with G3-4 neutropenia in 56%, anemia in 27% and
thrombocytopenia in 21% of the patients.
27% of patients had febrile neutropenia.
Three toxic deaths were observed, all in patients with
PS ≥ 1: two patients with sepsis and febrile neutropenia
and one for heart failure in a cardiopatic patient.Figure 1 Overall Survival in limited and extended disease.Nonhematologic toxicity consisted mainly of asthe-
nia (27%), mucositis (14%), nausea and vomiting (14%)
(Table 3).
Discussion
Small cell lung carcinoma (SCLC) which constitutes
about 15% of all lung cancer, is a very aggressive tumor
with a tendency for early metastasis [1].
Targeted therapy agents are widely used in NSCLC,
but no one is approved for use in SCLC; in fact all the
clinical trials investigating biological agents in SCLC,
yielded negative results.
Imatinib did not demonstrate clinical efficacy even in
patients with c-kit expression [13].
Vandetanib failed to demonstrate efficacy as a main-
tenance therapy and cediranib failed to demonstrate ob-
jective responses in recurrent or refractory SCLC [14].
Despite its peculiar chemo and radio-sensitivity, long
term survival is achieved in a small minority of patients
and combination of cisplatin and etoposide (PE) still
represent the standard of care after 25 years; with this
Figure 2 Time to progression in the limited and extended disease.
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patients but median survival of 7–8 months in ED [7].
Two randomized phase 3 trials evaluated doxorubicin-
based chemotherapy compared with platinum-based
chemotherapy in SCLC. Baka et al. enrolled patients with
either LD or ED- SCLC who were randomized to doxo-
















Heart failure 2six cycles. There were no differences in response rates or
in median survival time for LD (10.9 vs 12.6 months) and
ED (8.3 vs 7.5 months) [15].
A Cochrane systemic review of platinum vs non-
platinum chemotherapy regimens evaluated 29 trials with
5530 patients and concluded that platinum-based chemo-
therapy regimens did not offer a statistically significant
benefit in either overall response or survival compared to
non-platinum chemotherapy.
Subsequentely, a Japanase study, in 2002, reported that
irinotecan and cisplatin combination resulted in a sub-
stantial improvement in survival compared with treatment
with PE (median survival 12.8 vs 9.4 months) in ED [16].
The authors concludes that the combination of irino-
teca and cisplatin was an attractive option for patients
with metastatic small-cell lung cancer who have a good
performance status.
Numerous other drugs have been studied in combin-
ation with platinum, without substantial improvemet in
median survival or response rate.
Combination chemotherapy of belotecan (is a new
camptothecin-derivative antitumor agent that belongs to
the topoisomerase inhibitors) and cisplatin showed promis-
ing efficacy comparable to currently available standard regi-
men with favorable non-hematologic toxicity profile [17].
However, its high hematologic toxicity profile seems to
preclude general acceptance of this regimen as option
for treatment of SCLC. We are wainting for the result of
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ficacy of belotcan plus cisplatin to etoposide plus cis-
platin in patients with ED SCLC.
Recent data with newer agents as thalidomide and
bevacizumab, allow some cautious optimism for future
advances in the treatment of this complex and challen-
ging disease.
Strategies that have evaluated an increase of total dose,
of dose intensity, number of courses, or number of drugs,
or alternation of non-cross-resistant drugs, have been un-
successful. These approaches are not recommended out-
side clinical trials [18].
Some evidence suggests that adding thoracic radiother-
apy to chemotherapy improves survival in patients with
extensive-stage SCLC who have a complete response out-
side the thorax and at least a partial response within the
thorax after three cycles of etoposide and cisplatin [19].
Immediate whole-brain radiotherapy is indicated in pa-
tients with brain metastases and intracranial hypertension
or other neurological emergencies. In some series of pa-
tients with SCLC or NSCLC and brain metastases, whole
brain radiotherapy combined with different chemotherapy
regimens seemed to increase the risk of neurological toxic
effects, but also to increase response rates and lengthen
the time to progression of brain metastasis [20,21].
This increase in toxic effects was probably related to
the use of anthracyclines and high doses of radiation per
fraction. On the basis of this evidence whole-brain
radiotherapy should be started after the completion of
chemotherapy in patients with brain metastases, with or
without symptoms, but not delivered concomitantly with
cytotoxic treatment.
Loehrer PJ et al., compared PEI regimen (cisplatin-
etoposide-ifosfamide) with PE regimen in previously un-
treated ED-SCLC. The results indicated that PEI regimen
was associated with a significant improvement in OS and
PFS, without significant difference in toxicity [10–12].
The Hoosier Oncology Group study showed an im-
proved time to progression (statistically different) and over-
all survival associated with PEI combination chemotherapy
(9.0 month versus 7.3 with PE regimen), in 171 patients
randomized from 1989 and 1993; in the previous study,
reported in 40 patients from 1987 to 1989, PEI regimen
produced a high complete remission rate in patients with
extensive disease.
Ifosfamide combination chemotherapy demonstrated a
durable complete remissions also in heavily pretreated
patients with recurrent germ cell tumors [22].
In our study, PEI regimen gave interesting results both in
LD and ED SCLC, with a remarkable median overall sur-
vival of 28.2 months in LD, and of 11.8 months in ED.
In both stages, the OS and TTP appear higher than
expected, comparing to the results obtained with PE
regimen published in the literature.Conclusions
SCLC remains a disease with disappointing results and
no good news coming from the research. In extended-
stage disease new drug combinations and approaches
did not result in any improvement in overall survival,
that remains the ultimate goal as, unlike in other che-
mosensitive cancers, second-line treatment is not an op-
tion for most patients.
Many other strategies, including maintenance therapy,
dose-intense, dose-dense chemotherapy and alternating
regimens have failed to demonstrate consistent benefits,
often with unacceptable toxicity.
In the absence of a firm evidence of any activity of bio-
logical agents, PEI regimen, in our opinion, may be a
possible therapeutic option, with high activity and an ac-
ceptable toxicity profile.
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